What the Research Says About Lutein, Zeaxanthin, and Age-Related Macular Degeneration

Editorial note: We only cite studies published in peer-reviewed journals. We summarize findings without overstating conclusions.

Published in the peer-reviewed journal Nutrients in February 2022, a review by researchers at the Medical University of Lodz (Poland) examined the current state of scientific knowledge on two plant-derived pigments – lutein and zeaxanthin – and their relationship to age-related macular degeneration (AMD), the leading cause of vision loss in older adults in developed countries. The full study is available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8874683/

What Are Lutein and Zeaxanthin?

Lutein and zeaxanthin belong to a family of plant pigments called carotenoids – the same broad category responsible for the orange color of carrots and the red color of tomatoes. More specifically, lutein and zeaxanthin are classified as xanthophylls, a subgroup of carotenoids that contain oxygen in their molecular structure.

The human body cannot produce these compounds on its own. They must come entirely from food. The richest dietary sources are dark leafy green vegetables. Kale leads by a wide margin, containing approximately 39.5 mg per 100 grams. Spinach follows at around 11.9 mg per 100 grams. Other meaningful sources include lettuce, broccoli, Brussels sprouts, green peas, and egg yolk.

Most adults in developed countries consume only about 1 to 2 mg of lutein per day – well below what many researchers consider a beneficial intake level. The authors cite a general reference intake recommendation of approximately 10 mg per day for lutein and 2 mg per day for zeaxanthin, though no official regulatory daily requirement has been formally established for lutein specifically.

Why the Eye Concentrates These Two Compounds

Of the more than 600 types of carotenoids found in nature, and the roughly 20 that circulate in human blood, only lutein and zeaxanthin accumulate in the retina. This selective concentration is not a coincidence – it reflects the specific biological role these pigments play in vision.

The macula is the small central region of the retina responsible for sharp, detailed vision. Lutein and zeaxanthin collect there in concentrations far higher than in any other tissue in the body. For this reason, they are referred to as “macular pigments.” A third compound, mesozeaxanthin, also accumulates in the macula, but unlike lutein and zeaxanthin, it is not obtained directly from food – it appears to be converted from lutein within the eye itself, through a process involving a retinal enzyme called RPE65.

The distribution of the two pigments within the eye is not uniform. Zeaxanthin is the dominant compound at the very center of the fovea – the highest-resolution area of the retina, where cone photoreceptors are most densely packed. Lutein is more broadly distributed across the surrounding macula and into the peripheral retina. This division of territory appears to reflect the distinct roles each compound plays in protecting the eye.

The eye uses specialized binding proteins to capture and hold these pigments in place. A protein called StARD3 binds lutein, while a protein called GSTP1 binds zeaxanthin and mesozeaxanthin. Without these proteins, the retina could not selectively accumulate the pigments at useful concentrations.

How These Pigments Protect the Eye

The review describes two primary mechanisms by which lutein and zeaxanthin protect retinal tissue:

1. Filtering Harmful Blue Light

The visible light spectrum includes a band of short-wavelength blue light (roughly 400 to 500 nanometers) that is particularly damaging to retinal tissue. Blue light generates reactive oxygen species – unstable molecules that damage cell membranes and DNA – more efficiently than longer-wavelength light. The study cites research showing that blue light at 440 nm requires one hundred times less energy to cause retinal damage than orange light at 590 nm.

Lutein and zeaxanthin are yellow pigments that absorb this range of blue light before it reaches the photoreceptor cells beneath them. They function, in effect, as a natural optical filter built into the tissue of the eye itself.

2. Neutralizing Free Radicals

Beyond their role as a light filter, these carotenoids act as direct antioxidants. The retina is an environment of high oxygen tension and constant light exposure – conditions that continuously generate free radicals. Lutein and zeaxanthin can neutralize multiple types of these reactive molecules, including singlet oxygen, hydroxyl radicals, and lipid peroxyl radicals.

The review notes that the antioxidant potency of these pigments is related to the number of double bonds in their molecular structure. Zeaxanthin, with 11 conjugated double bonds, has a somewhat higher capacity to quench singlet oxygen than lutein, which has 10. The study also notes that the antioxidant capacity of macular carotenoids exceeds that of vitamin E in the retinal environment.

Additionally, researchers have found that these pigments may help reduce glare and improve contrast sensitivity – the ability to distinguish objects from their backgrounds – by pre-filtering scattered light before it reaches the photoreceptors. Multiple clinical studies cited in the review found that higher macular pigment concentrations correlate with better performance under glare conditions.

What the Research Shows About AMD

Age-related macular degeneration involves the deterioration of the macula and is the leading cause of blindness among older adults in developed countries. AMD exists in two primary forms: a dry form (the more common early-stage condition involving gradual tissue breakdown) and a wet form (involving abnormal blood vessel growth beneath the retina, which tends to cause more rapid vision loss). The disease typically begins as dry AMD and progresses to the wet form in roughly 10 to 20 percent of cases.

The scale of the problem is significant. The study projects that by 2040, approximately 288 million people worldwide will have some form of AMD. The primary risk factors identified in the research are age, sunlight exposure, smoking, and poor nutritional status.

The review finds a consistent inverse relationship between macular pigment levels and AMD risk: people with lower concentrations of lutein and zeaxanthin in the macula are more likely to develop the disease, and AMD patients tend to have measurably lower levels of these pigments than healthy individuals of the same age.

The AREDS Trials: The Most Important Clinical Evidence

The most significant clinical evidence discussed in the review comes from two large-scale trials sponsored by the U.S. National Eye Institute: AREDS (Age-Related Eye Disease Study) and its follow-up, AREDS2.

The original AREDS trial, published in 2001, tested a formulation of antioxidant vitamins and zinc in people at moderate-to-high risk of AMD progression. The results showed a 25 percent reduction in the risk of advancing to late AMD among participants who took the supplement formula. Notably, the original AREDS formula did not include lutein or zeaxanthin – it used beta-carotene instead as the carotenoid component.

AREDS2, conducted between 2006 and 2012, modified the formula by replacing beta-carotene with lutein (10 mg) and zeaxanthin (2 mg) and adding omega-3 fatty acids. The primary analysis found that the reformulated supplement did not improve outcomes compared to the original AREDS formula overall. However, a secondary analysis – which the authors highlight – found that participants who took the AREDS formula with added lutein and zeaxanthin experienced a 31 percent reduction in progression from dry AMD to advanced AMD, compared to the 25 percent seen in AREDS1. The study also confirmed that supplementation with lutein and zeaxanthin significantly increased measured serum levels of these compounds – by 190 to 210 percent above baseline – over the course of the study.

It is important to be precise about what this evidence shows: these trials were conducted in people who already had intermediate-stage AMD or advanced AMD in one eye. The findings demonstrate a slowing of progression in people with existing disease. They do not establish that supplementation prevents AMD from developing in the first place, though epidemiological research is suggestive in that direction.

Dietary Food Sources vs. Supplementation

The review is careful to note that supplementation and diet are not equivalent. The authors state directly that no supplement regimen can replace a well-chosen diet. Multiple studies have shown that regular consumption of foods high in lutein and zeaxanthin – particularly spinach, kale, and cabbage – is associated with meaningful protection against the progression to late AMD.

Cooking and food preparation affect bioavailability. Lutein and zeaxanthin are fat-soluble, meaning they are absorbed much more efficiently when consumed with dietary fat. Heat treatment of vegetables actually increases bioavailability by breaking down cell membranes and releasing the pigments from protein complexes. Finely chopping vegetables before eating also improves absorption.

Genetic Risk and Dietary Response

The review addresses an important nuance: not all individuals respond equally to dietary lutein and zeaxanthin. Certain genetic variants are associated with significantly increased AMD susceptibility. A variation in the complement factor H (CFH) gene – specifically the Y402H variant – has been found to increase AMD risk by up to eleven times. A variant in the ARMS2 gene can increase risk by up to fifteen times. The review cites research suggesting that higher antioxidant intake, including lutein and zeaxanthin, may be particularly important for individuals carrying these genetic risk factors.

Beyond the Eye

While the review’s primary focus is on AMD, it notes that lutein and zeaxanthin accumulate in other tissues as well, including the skin, lungs, adrenal glands, and brain. Research cited in the review indicates that lutein is the predominant carotenoid in human brain tissue and that its concentration in the macula and occipital cortex are correlated. This finding connects visual health to broader cognitive health in ways that continue to be studied.

Summary of Key Takeaways

• Lutein and zeaxanthin are the only dietary carotenoids that accumulate specifically in the human retina and macula. They cannot be produced by the body and must come from food or supplements.
• Their primary protective roles are filtering short-wavelength blue light and neutralizing free radicals that would otherwise damage retinal tissue.
• AMD is a major and growing global health problem with limited treatment options, particularly for the dry form.
• People with AMD tend to have lower macular pigment levels than healthy individuals, and higher dietary intake is consistently associated with lower risk of disease progression.
• The AREDS2 clinical trial demonstrated a 31 percent reduction in AMD progression to advanced stages among participants supplemented with lutein and zeaxanthin, compared to 25 percent with the original AREDS formula.
• The research supports dietary intake through dark leafy greens as the foundation, with supplementation as a documented adjunct particularly in people already diagnosed with AMD.
• Genetic factors can substantially modify individual risk and may influence how much benefit a person receives from increased lutein and zeaxanthin intake.

Source: Mrowicka M, Mrowicki J, Kucharska E, Majsterek I. Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration—Neurodegenerative Disease. Nutrients. 2022 Feb 16;14(4):827. doi: 10.3390/nu14040827. Full text available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8874683/